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NOS-BASED BIOPOLYMERS; TOWARDS NOVEL 
THROMBORESISTANT NO-RELEASE MATERIALS  
 
CHARBEL ABOU DIWAN 
ABSTRACT 
 
 Nitric Oxide releasing biopolymers have the potential to 
prolong vascular graft and stent potency without adverse systemic 
vasodilation. It was reported in literature that eNOS-overexpressing 
endothelial cell seeding of synthetic small diameter vascular grafts 
decreased human platelet aggregation by 46% and bovine aortic smooth 
muscle cell proliferation by 67.2% in vitro. We hypothesized that 
incorporating the enzyme nitric oxide synthase (NOS) in biocompatible 
polymeric matrix will provide a source of NO that utilizes endogenous 
compounds to maintain an unlimited supply of NO. To test this 
hypothesis, we have incorporated the enzyme nitric oxide synthase into a 
polyethyleneimine film using a layer-by-layer electrostatic deposition. 
This approach will provide a source of NO that utilizes endogenous 
compounds available in the blood matrix to maintain a constant supply of 
NO at the blood/device interface. When coated onto the surface of 
various blood-contacting implantable medical devices, it will provide NO 
 v
fluxes at levels equal or greater than the normal endothelial cells, and for 
extended time periods. This configuration will help solve the issues of 
both thrombosis and stenosis that occur as side effects for several types 
of biomedical implants.  
Our results indicate a proof of principle of a new approach for 
making antithrombotic coatings for medical devices and implants based 
on NO release. We have demonstrated that NOS-based polymetric films 
successfully generate NO under physiologic conditions at small levels 
equal to and higher than those observed for endothelial cells. The level of 
NO release can be fine-tuned through varying the number of NOS layers 
in the film buildup. We have shown that NO fluxes from our NOS-based 
PEI films are sustained for prolonged periods of time, which has the 
potential of producing efficient, short and long-term, antithrombotic 
coatings for medical devices and blood-contacting tools such as stents 
and catheters. We also show that NO release from these coatings 
successfully decrease platelet adhesion at the surface by 60%. This, and 
other properties are key for the desired thromboresistivity needed for 
blood-contacting medical devices. 
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CHAPTER I 
INTRODUCTION 
 
1.1 BIOCOMPATIBILITY ISSUES OF IMPLANTABLE 
MEDICAL DEVICES 
 
The thrombogenic nature of various polymeric materials utilized to 
prepare various blood-contacting and implantable medical devices such 
as vascular grafts, intravascular catheters and sensors, coronary artery 
and vascular stents, even if labeled as biocompatible, can cause serious 
complications in patients [2]. Upon introduction of a foreign material into 
the blood stream, key proteins of the coagulation cascade (fibrinogen, 
and von Willebrand’s factor) adsorb to the surface, followed by platelet 
adhesion and activation, leading to fibrin and thrombus formation at the 
surface (Figure 1.1) [3]. 
 2
 
 
 
 
Figure 1.1: Illustration showing thrombus formation at the surface of 
implantable medical devices. Upon exposure to blood, protein adsorption 
occurs, followed by platelet adhesion at the surface. Platelet activation 
leads to thrombus formation at the surface. 
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An anti-coagulation regiment, with the adverse effects associated 
with long term use, is typically required to clinically reduce the risk of 
thrombus formation [4]. Thrombus formation and generation involves 
two synergistic events; a cGMP-dependant mechanism that involves 
platelet activation, adhesion and aggregation [5], and fibrin formation 
resulting from the binding of bivalent fibrinogen to glycoprotein IIb/IIIa  
[6]. 
In addition to thrombus formation, certain medical devices, during 
the implantation process can damage the endothelium lining of blood 
vessels, leading to smooth muscle cell proliferation, and ultimately cause 
vascular stenosis via neointimal hyperplasia [7,8]. Further more, bacterial 
adhesion at the material surface of medical devices leads to device-
associated infections [9]. Early bacterial adhesion is mediated by 
reversible bacteria-substrate interactions, followed by irreversible 
molecular bridging at longer times [10]. Upon adhesion, certain bacteria 
are capable of secreting an exopolysaccharide matrix forming a 
protective biofilm that retains nutrients and protects the bacteria from the 
host immune response. Biofilms provides bacterial resistance to 
traditional antibiotic therapies [11] . 
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Implantation into subcutaneous tissues subjects implants to an 
inflammatory response involving the release of fluid and plasma proteins 
followed by the recruitment of leukocytes at the implant site. Neutrophils 
and monocytes migration and adhesion to the implant surface initiates 
phagocytosis. After the initial inflammatory response, a more chronic 
response involves a sustained inflammation at the implant site involving 
the recruitment of macrophages, monocytes, and lymphocytes. 
Eventually, a fibrous capsule composed mainly of macrophages and 
collagen is formed around the implanted device.  
 
1.2 THE PROTECTIVE ROLE OF ENDOGENOUS NITRIC 
OXIDE (NO)  
 
Endogenous NO production at low concentrations (nanomolar) 
plays a critical role in the regulation of vascular hemostasis [12]. 
Endothelium derived NO production inhibits platelet adhesion [13], 
aggregation [14], and their further recruitment to the growing thrombus 
[15]. NOS inhibition is associated with the shortening of bleeding times 
in healthy volunteers [16], and platelet accumulation in the vasculature of 
animals [17]. In vivo studies involving production of high levels of NO 
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from iNOS showed the ability to prevent platelet adhesion [18]. NO, 
prostacyclin, and ecto-AD(T)Pase are potent inhibitors of platelet 
function that are produced by an intact endothelium [19]. Nitric oxide 
diffuses into platelets stimulating cGMP production by soluble guanylyl 
cyclase causing a decrease in cytosolic Ca2+ levels by directly inhibiting 
voltage-gated Ca2+ channels [20]. Calcium acts as an important second 
messenger with an intracellular concentration 50-100nM in resting 
platelets. Upon platelet activation, intracellular calcium concentrations 
can rise up to 1mM [21], triggering a cascade of events that leads to 
platelet aggregation.  
The regulatory effect of NO on cGMP and cGMP-dependant 
protein kinases was reported by a significant increase in platelet 
aggregation in the presence of guanylyl cyclase inhibitors [22,23], and by 
the potentiation of anti-platelet effects in the presence of cGMP 
phosphodiesterase inhibitors [24]. Reduction in Ca2+ levels via a cGMP 
dependant mechanism inhibits thrombin mediated activation of 
phosphoinositide 3-kinase (PI-3 kinase) [25,26] leading to a suppression 
of the conformational change of glycoprotein IIb/IIIa required for 
fibrinogen binding [27], which decreases the number and affinity of 
fibrinogen binding sites on the platelet surface [28]. cGMP is also 
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involved in increasing intracellular cAMP indirectly by inhibiting the 
phosphodiesterase III (PDE III) dependant degradation of cAMP [29]. 
Increased levels of cAMP has been associated with decreased levels of 
intracellular Ca2+ flux [30,31]. In addition cGMP down-regulates protein 
kinase C leading to regulation of the surface expression of α granule 
protein P-selectin, a mediator of platelet adhesion [32].  
There have been various reports indicating NO release from resting 
[33] and aggregating platelets [24,34]. NO levels from activated human 
platelets have been indirectly measured and is estimated at 11.2 
pmol.min-1/108 cells [33]. NO temporarily inactivates platelets in the 
close proximity of the endothelium [35-37]. This inhibition is short-lived 
and NO is rapidly scavenged by oxygen and hemoglobin in plasma 
[38,39].  
NO is produced by macrophages as part of the natural immune 
response to bacterial infections [40,41]. NO is shown to mediate the 
inhibition of a wide variety of Gram-negative and Gram-positive 
bacterial species [42], as well as reducing bacterial adhesion [43]. 
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1.3 THE ROLE OF NO-RELEASING MATERIALS AS 
COATINGS FOR IMPLANTABLE MEDICAL DEVICES 
 
  Considerable research is being focused on improving the 
surface chemistry of materials used as outer coatings of implantable 
medical devices [3]. NO releasing polymers have the potential to be 
effective in preventing platelet adhesion, activation, and aggregation onto 
the surfaces, therefore reducing the risk of thrombus formation at these 
surfaces. They have the potential to prolong vascular graft and stent 
potency without adverse systemic vasodilation [44]. NO exhibits a short 
half-life <1s in the presence of oxygen and hemoglobin, there is no 
systemic effects that can be caused by the NO-releasing coatings because 
any NO released will be rapidly consumed locally near the surface of the 
device [45]. Numerous approaches are currently being investigated in an 
attempt to develop polymeric materials that are more blood-compatible. 
In general, these approaches can be categorized into two main trends: 
first, methods that mimic endothelial cells anti-thrombogenic properties 
[46-50], and, second, methods that use modified chemical surfaces and 
added moieties that exhibit decreased protein and cell adhesion [1]. 
Prevention of protein adhesion in vivo is generally difficult to achieve, 
therefore the other approach, which aims at the development of NO-
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releasing surfaces akin to native endothelial cells, appears more 
promising. Nitric oxide, thrombomodulin, prostacyclin, and heparans 
contribute to the non-thrombogenic properties of the endothelial cells 
[2,51]. Polymers that possess chemical platforms with the ability of 
releasing NO have been shown to be more thromboresistant. A potential 
solution can be found in polymeric materials that are capable of releasing 
low levels of nitric oxide at the blood/polymer interface.  
 
1.4 CLASSES OF NO-RELEASING MATERIALS 
 
  Two classes of NO-releasing materials have been explored 
(Figure 1.2). N-diazeniumdiolate based NO-releasing polymers [52-56], 
and Nitrosothiol-based NO-releasing polymers [57-61] . 
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Figure 1.2: Generic structure of (A) Diazeniumdiolates (I) 
zwitterionic, (II) cation stabilized. (B) S-Nitrosothiol. Adapted 
from [1] 
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1.4.1 N-Diazeniumdiolates 
 
  N-diazeniumdiolates are inorganic NO donors formed by the 
reaction of a secondary amine structure with 2 moles of NO gas under 
high pressure, creating a relatively stable adduct structure [62-64]. A 
countercation is required to fulfill electroneutrality of the negatively 
charged diazeniumdiolate adduct, leading to zwitterionic molecules [1]. 
Three general structural types of diazeniumdiolates have been outlined 
for preparing diazeniumdiolates based NO-releasing polymers: Dispersed 
non-covalently bound small molecules where the diazeniumdiolate group 
is attached to amines in low molecular weight compounds; covalently 
bound diazeniumdiolates group to polymeric side chains or to the 
polymeric backbone [56].  
  Since this initial work, additional methods for preparing NO-
releasing polymers utilizing diazeniumdiolates as NO donors were 
described by both Pulfer et al. [55] and Zhang et al. [54] Pulfer and co- 
workers developed NO releasing PEI microspheres that were entrapped 
into vascular grafts pores [55]. Zhang and co workers prepared 
diazeniumdiolate nanoparticles by reacting NO with alkylamines tethered 
onto the surface of fumed silica particles (7-10nm diameter) [54]. 
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Diazeniumdiolated-dimethylhexyldiamine (DMHD/N2O2) were used to 
prepare NO-releasing polymers as coatings for oxygen sensors [65], and 
extracorporeal circuits [46]. In other studies, diethylenetriamine 
diazeniumdiolate (DETA/ N2O2) was embedded into ethylene-vinyl 
acetate [66,67]. In other work, diazeniumdiolate-spermine (SPER/N2O2) 
was incorporated into a biodegradable polymer used to construct jugular 
vascular grafts [68]. Although initial studies proved the worthiness of 
such materials, leaching of the water-soluble diazeniumdiolates was 
shown to form nirtosoamine, a well known class of carcinogens, due to 
the oxidation of local NO to an NO+ intermediates that form RN-NO 
species upon reactions with amine compounds [69]. To counter this 
problem, more lipophilic discrete dialkyldiamine diazeniumdiolates such 
as dibutylhexyldiamine diazneniumdiolate (DHBD/N2O2) were prepared 
that have higher octanol/water partition coefficients and would be more 
likely to stay in polymer phase, even if nitrosoamine formation occurs 
[44]. The use of a diazeniumdiolate substrate that would be benign upon 
leaching was used as another method to avoid the buildup of 
carcinogenic species. The amino acid L-proline was used to prepare the 
anionic diazeniumdiolate of proline (PROLI/N2O2), and thus the 
nitrosamime form of proline is non- carcinogenic and would therefore be 
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harmless to the patient [70]. The covalent attachement of 
diazeniumdiolate moiety to the polymer backbone was used to prevent 
leaching of any potentially carcinogenic species. Diazeniumdiolated 
silicone rubbers were prepared by the use of diamino- and triamino-
alkyltrimethoxysilanes cross-linkers with hydroxyl terminated 
polydimethylsiloxanes followed by reaction with NO [48]. Anionic 
diazeniumdiolated polymethacrylates were prepared by copolymerizing 
various secondary amine-containing monomers with methyl-methacrylate 
[71]. A protected diazeniumdiolated poly(vinyl chloride) was synthesized 
by using the O(2)-alkylated diazeniumdiolate of piperazine as a linker for 
incorporation of the diazeniumdiolate onto the polymeric backbone [72]. 
Alternative matrices for the incorporation and covalent attachement of 
diazeniumdiolates have been investigated and include sol-gels and 
hydrogel dressings. Discrete diazeniumdiolates (DETA/N2O2), 
dipropylenetriamine diazeniumdiolates (DPTA/N2O2), and DPTA/N2O2-
g-dextran, were suspended in a hydrogel matrix [73]. The synthesis of sol 
gel materials by reaction of alkoxylsilanes with alkyltrimethoxysilanes 
followed by exposure to NO has been reported [74]. In addition, 
hydrogels as NO carriers were prepared by reacting polyethylene glycol 
N-hydroxysucinimide monoacrylate with poly L-lysine and then 
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dissolving the product in water followed by the exposure to NO [57], and 
by the reaction of NO with cross-linked poly(vinyl-acetate) modified 
with amine groups [75].  
 
1.4.2 S-Nitrosothiols 
 
  The second class of NO donors are S-nitrosothiols; they are 
thought to serve as NO reservoirs and transporters within biological 
systems [76]. S-Nitroso-albumin and S-nitrosoglutathione are the most 
abundant naturally occurring S-nitrosothiols circulating in blood [77]. 
The cleavage of the S-NO bond releases NO by three known mechanisms 
[78]: copper mediated decomposition[79], the direct reaction of ascorbate 
[80], and photolytic decomposition [81]. S-nitrosothiols have been 
covalently linked to the polymer to prevent leaching of the donor or 
reaction byproducts. NO releasing hydrogels were prepared by linking 
cysteine to Polyethylene glycol (PEG) and reacting the resultant 
copolymers with sodium nitrite to form S-nitrosocysteine groups [57]. 
The S-nitrosothiol (GSNO) and S-nitroso-N-acetylcysteine (SNAC) were 
blended into poly(ethylene oxide) and poly(propylene oxide) copolymers 
or PEG for targeted deliver of NO in biomedical applications [58,59]. In 
 14
addition, S-nitrosothiols can be tethered to the surface of polymer fillers. 
S-nitroso-N-acetylpenicillamine (SNAP) was tethered to the surface of 7-
10nm diameter fumed silica particles [82].  
 The greatest limitation of these approaches is that they are a finite 
reservoir of NO, which will limit their potential use in more permanent 
types of implants, and the NO fluxes achieved so far are lower than NO 
released from endothelial cells [1]. Studies have shown that stimulated 
human endothelial cells continuously generate NO at a level of ca. 4x10-
10mol.cm-2.min-1 [83]. 
 
1.5 NOS BASED NO-RELEASING MATERIALS 
 
 The logical alternative is then to explore approaches that would lead 
to materials with the ability to sustain NO generation for longer 
durations. Some current developments include materials that utilize 
endogenous NO donors such as S-nitrosothiols and nitrite to generate NO 
[84-86]. Though these approaches display potential, with their current 
limitations, it is not likely to overcome the complexity of the 
biocompatibility issues of medical devices. 
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 Developing a NO-releasing surface that closely resembles the 
endothelium is the key to achieving better thromboresistivity. The 
endothelial isoform of the enzyme Nitric Oxide Synthase, eNOS, is a key 
component of the endothelial cell lining. It was reported that eNOS-
overexpressing endothelial cells seeding of synthetic small diameter 
vascular grafts decreases human platelet aggregation by 46% and bovine 
aortic smooth muscle cell proliferation by 67.2% in vitro [87]. NO 
releasing materials using Polyethyleneimine (PEI), a biocompatible 
polymer [88], has been reported in literature [55,89,90].  In our lab, NO 
was successfully generated from the enzyme Nitric Oxide Synthase 
embedded in bilayered cast film of didodecyldimethylammonium 
bromide surfactant [91]. We have incorporated the oxygenase domain of 
the enzyme Nitric Oxide Synthase (NOSoxy) in a Polyethyleneimine 
polymeric matrix by means of layer-by-layer electrostatic adsorption 
[92,93] to construct a multi-component protein film that mimics the NO-
generating behavior of the endothelial cell lining. We have demonstrated 
that our films provide a source of NO that utilizes endogenous 
compounds to maintain a continuous supply of NO at levels that are in 
the same range as that of endothelial cells [94].   
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CHAPTER II 
 
LAYER-BY-LAYER ASSEMBLY OF PROTEIN FILMS 
 
2.1 INTRODUCTION 
 
The technique of ultrathin film assembly via alternate adsorption 
of oppositely charged polyions was developed a couple of decades ago. 
In 1991, the alternate adsorption of linear polycations and polyanions as a 
method for film assembly was first introduced by Decher and co-workers 
[1-9]. The basis of this method is the excessive adsorption at every stage 
of the polycation/polyanion assembly that leads to recharging of the 
outermost surface at during the film formation.  
This methodology relies on the following principle: a negatively charged 
substrate surface is immersed in a cationic polyelectrolyte solution 
allowing the electrostatic adsorption of the polycationic layer. Since high 
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concentrations of polyelectrolytes are utilized, a number of cationic 
groups remain exposed and thus the surface charge is effectively 
reversed. After rinsing with water, the substrate is immersed in an 
anionic polyelectrolyte solution restoring the original surface charge. By 
repeating both steps, alternating multilayer assemblies are obtained with 
repeatable layer thickness (scheme 2.1) [10].   
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Figure 2.1: Scheme of layer-by-layer film assembly on a solid substrate 
by alternate adsorption of linear polycations and polyanions/negatively 
charged proteins.  
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Electrostatic layer-by-layer self-assembly has been applied to thin 
film coatings [6,11-13]. It allows the assembly of multilayers of materials 
on two-dimensional (2D) supports and on three-dimensional (3D) 
nanotemplates [14]. A variety of charged materials have been used in 
these 2D and 3D nanoassembly processes; they include linear 
polyectrolytes (synthetic and natural), enzymes, antibodies, viruses, and 
inorganic nanoparticles [14]. The resulting film architecture can be 
designed to meet different requirements such as biocompatibility, 
stability, and thickness, typically on the order of tens to hundreds of 
nanometers [14,15]. Layer-by-layer organized film assembly based on 
the alternate adsorption of oppositely charged macromolecules paves the 
way for a molecular architecture in the direction perpendicular to the 
solid support allowing for the design of films with nanometer resolution. 
Ultrathin films can be designed with definite molecular composition and 
ordered architecture in the range of 5-1000 nm with a precision better 
than 1nm [16]. Layer-by-layer assembly allows the control of the 
chemical composition of the films, which translates into control of the 
biological activity in biomedical applications. Ultrathin film coatings of a 
surface can maintain its original mechanical properties and structure [17].  
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For enzyme-based thin films, electrostatic adsorption seems to be 
one of the simplest ways for enzyme immobilization [15]. Other 
available methods of enzyme immobilization include physical adsorption 
[18], encapsulation [19], or covalent attachment [20,21]. However, these 
methods have disadvantages in terms of stability and low active site 
accessibility/activity. Site-targeted immobilization is complex but can 
provide enhanced activity if the immobilization does not interfere with 
enzyme function [22-24].    
 
2.2 GENERALITY OF THE ASSEMBLY PROCEDURE 
 
Layer-by-layer assembly of multilayered protein films has been 
performed by means of alternate electrostatic adsorption of either 
positively charged polyethyleneimine (PEI), poly(allylamine) (PAA), 
poly(dimethyldiallylammonium) (PDDA), or negatively charged 
poly(styrenesulfonate) (PSS), DNA, and heparin [8,10,25-38]. The pH of 
the protein component was set far from the isoelectric point in order to 
ensure sufficient charge under experimental conditions. The 
concentration range of aqueous proteins was 0.1 – 2 mg/ml or ~ 10-5M. 
Examples of aqueous proteins used (table 2.1) were cytochrome c, 
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lysozyme, histone type YIII-S, myoglobin (Mb), pepsin, horseradish 
peroxidase (POD), hemoglobin, glycoamylase (GAM), concanavalin A 
(Con A), albumin [31], Glucose Oxidase [21,10,32], catalase, invertase, 
diaphorase [8,10], bacteriorhodopsin [37], and immunoglobulin (IgG) 
[33,39]. Protein stability can be affected by the surface structure of the 
solid support; therefore precursor films of alternate PEI/PSS were used as 
standard surfaces [8,10,29,40]. Solid surfaces are typically immersed in 
aqueous protein solutions or polyions for 20 minutes. Surfaces were then 
rinsed with water, and dried. To reach saturation of the adsorption 
process, the assembly process was carried out uninterrupted. A summary 
of the alternate adsorption of 18 water-soluble proteins in combination 
with oppositely charged polyions is listed in Table 2.1. 
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  Unlimited cycling of proteins with oppositely charged polyions 
is reported. The mass changes were determined as a function of 
frequency shifts with Quartz Crystal Microbalance (QCM) measurments 
and was quite reproducible. An alternation with a polyion is required due 
to the unsuccessful attempts to grow protein films by the cyclic 
immersion of a substrate into a protein solution.  
  QCM, x-ray reflectivity, scanning electron microscopy, and 
surface plasmon resonance were the tools used to estimate protein layer 
thicknesses. These estimates correspond to known molecular dimensions 
of proteins obtained from crystallographic data and suggest the formation 
of relatively uniform monolayers. Parameters such as orientation, 
packing density, and hydration of proteins within the layer, might have 
significant influence on the thickness of the protein monolayer.  
The multilayer formation as indicated in Figure 2.1 is quite 
general. The physical separation of the individual layers in the films is 
assumed on the basis of the regular, stepwise mass increase during the 
assembly. However, the layer separation between the proteins and the 
oppositely charged polyions may not be as definite, and the linear 
polyions would cover the protein surface and act as bridging molecules, 
to enhance protein stability.  
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Altering the pH around the isoelectric point allows the protein to 
be assembled with polyanions and polycations. The protein can be used 
at a pH above the isoelectric point (i.e. negatively charged) to assemble 
with polycations and at a pH below the isoelectric point (i.e. positively 
charged). Examples of both cases are hemoglogbin/PEI+, 
hemoglobin/PSS-, and albumin/PDDA, or heparin- multilayers (table 2.1). 
The layer-by-layer immobilization of proteins onto solid substrates with 
strong polyions (such as PSS, PEI, PDDA) renders it insoluble in a buffer 
for a pH range between 3 and 10. Immobilization of proteins with weak 
polyions renders it partially soluble in buffers with pH close to the 
isoelectric point of one of the components.  
Lvov and co-workers demonstrate the dependence of QCM 
frequency shift on cycles of alternate Myoglobin (Mb) 
/Polystyrenesulfonate (PSS) adsorption. QCM shifts were proportional to 
the adsorbed mass at the surface of quartz crystals, and correspond to 
protein monolayer formation at every step of the film formation process 
[8,10]. Figure 2.2 represent the typical UV/vis spectra for a Mb/PSS film 
at consecutive steps of the assembly, with a linear increase in the Soret 
band absorbance (407nm) with the number of myoglobin layers in the 
film. 
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Figure 2.2: UV/vis spectra of Mb/PSS assembly. The lowest spectrum 
corresponds to a precursor film. The following spectra correspond to the 
stages after adsorption of 2,4,6,8,10, and 12 alternate MB/PSS layers. 
Adapted from [10] 
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  The assembly of glucose oxidase films (GOD/PEI) was 
reported by Lvov and co-workers [10]. The adsorption kinetics of this 
process yielded GOD adsorption saturation in 15 minutes. Linear film 
mass increases were observed up to at least 21 molecular layers. The 
layer thickness for GOD was 34.4nm and 0.8nm for PEI. In addition, 
with increasing numbers of GOD layers, a linear increase of the UV/Vis 
absorbance was observed [10]. 
The alternate assembly of glucose oxidase with PDDA was also 
reported [10,32]. Layer thicknesses observed with each adsorption cycle 
of GOD (8nm with PDDA; 11.7nm with PEI at pH 7; 8.4nm with PAA) 
correspond to the diameter of the GOD molecule, suggesting a 
monolayer formation [10,32].  
  Atomic Force Microscopy (AFM) has been used to study 
surface morphology of multilayered films at every step of the adsorption 
process [41]. Surface roughness corresponded to the sequence of 
protein/polyion adsorption. With the protein layer, the surface roughness 
was larger and corresponded to the diameter of the globular protein used. 
The surface roughness decreased upon the deposition of the polyion 
layer.  
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2.3 BIOLOGICAL ACTIVITY AND ENHANCED STABILITY OF 
PROTEINS IN FILMS 
 
Proteins assembled with polyions by the layer-by-layer 
methodology tend to not denature [10,26,27,30,32,33,38]. The retention 
of enzymatic activities within the multilayered films was seen with 
glucose isomerase, glucoamylase, glucose oxidase, and peroxidase. 
Specific reactions was seen between immunoglobulins (IgG) and 
antibodies in the multilayered films [33]. The Soret band absorbance of 
myoglobin and hemoglobin was used to confirm their native 
conformations within the films [8,10,35]. Redox potentials of myoglobin 
and cytochrome P450 within those multilayered films corresponded to 
the redox potentials of these proteins immobilized onto electrode surfaces 
by other methods [35, 37]. 
Layer-by-layer immobilization of proteins with linear polyions enhanced 
their enzymatic stability, and preserved them from microbial attacks. 
GOD/PEI multilayered films retained 90% of enzymatic activity after 
incubation at 5°C for 3 months. In addition, GOD/PEI multilayered films 
show enhanced temperature stability and were active up to 67°C in 
comparison to 50°C for GOD in solution. Glucose oxidase retains its 
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activity within the multi-layered films up to pH 10 while it drops to a 
minimum at pH 9 in solution [32]. 
The enzymatic activity within the multilayered films increases linearly 
with the number of enzyme layers as seen with the GOD/PEI films up to 
10 protein layers; when the activity of the film reaches saturation [32]. 
Saturation in bioactivity is probably due to diffusion limitations of the 
substrate in penetrating the film. The extent of accessibility of the 
substrate to the proteins within the film depends greatly on the nature of 
the film component, due to the transport of the substrate through the 
multilayer, and thus puts restrictions on the number of enzyme layers 
within the multilayered films.  
 
2.4 PROBLEMS OF THE ASSEMBLY 
 
2.4.1 NONLINEAR GROWTH 
 
 Nonlinear film growth with adsorption cycles was seen in some cases, 
and it was possible to overcome it in order to reach protein monolayer 
formation at every adsorption step by the following methods: 
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1. Decreasing of protein concentrations, such as in the case of 
pepsin/PDDA, or alcohol dehydrogenase/PDDA films, from 
1mg/ml to 0.1mg/ml or less. IgG was also used for assemble at low 
concentrations (0.1mg/ml) [33]. 
2. Altering the pH of the protein solution in order to modulate the 
surface charge, as in the case of the GOD/PEI assembly from pH 
6.5 to 9.2 [32]. 
3. Altering the types of polyions used in the layer-by-layer assembly 
procedure. In the case of GOD, monolayer formation was achieved 
via the change from branched PEI to linear PDDA [10], or PAA 
[32]. 
 
2.4.2 CHARGED GROUPS ON A PROTEIN GLOBULE SURFACE 
 
Density and location of the charge 
 
 The density and location of the charge on the protein surface 
can be critical to the assembly process. The electrostatic attraction of 
proteins with linear polyions is straightforward, however, the situation is 
different with large ions with specific three-dimensional shapes and 
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charge distribution. As an example, the direct assembly of oppositely 
charged protein molecules was difficult due to the fact that electrostatic 
attractions cannot be maximized with globular proteins. Polyion 
anchoring appears to be favored by the “patched” nature of the surface 
charge of proteins [42]. Flexible linear polyions can produce optimized 
electrostatic attractions and hence may penetrate in between protein 
molecules acting as an electrostatic “glue”.  
 
The pH dependance   
 
The number of excess charges on protein surfaces is directly 
dependant on the pH. Typically, the number of elemental charges seen 
with proteins used in the assembly process ranges from 10 to 60. For 
example, an albumin globule gave an elemental charge of +35 at pH 4 
[31]. 
 
Dependence on the thickness of the underlying polyion layer 
 
 The amount of adsorbed proteins was found to depend on the 
thickness of the underlying linear polyion layer. Proteins deposited in 
alternation with polyions prepared from high ionic strength solutions 
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(thickness of polyion layer: 3-4nm) were thicker than the protein layers 
deposited in alternation with polyions prepared from water (thickness of 
polyion layer 1nm). In multilayers composed of myoglobin/PSS in 0.2M 
NaCl, the thickness of the myoglobin layer was of the order of 7nm, 
which is double the thickness of the 4nm myoglobin monolayer deposited 
in alternation with PSS from water [35]. The amount of immunoglobulins 
was found to be double in IgG/PSS in 0.1M NaCl multilayers when 
compared to a multilayer with PSS from water [33]. The thicker polyion 
layer provides a matrix with a greater area available for protein 
deposition, and hence requires more protein to achieve the charge 
compensation and reversal. Therefore, the variation in the ionic strength 
of the polyion solution may be used as a fine-tune properties of the 
protein surface in film buildup. 
 
2.4.3 RELIEF OF SOLID SUPPORT 
 
The stability of the multilayer assembly can be affected by the 
surface structure of the solid support. The assembly of hemoglobin, 
glucose oxidase, concanavalin, albumin, and myoglobin gave more stable 
films than those of cytochrome c and lysozyme. Multilayer assemblies 
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onto QCM resonator was successful on all those proteins, while some 
difficulties occurred with the assembly onto quartz slides such as in the 
case of the alternate assembly of lysozyme onto PSS. Protein multilayers 
exhibit high stability when deposited onto silver or gold electrode 
surfaces, which have roughness in the tens of nanometers range. 
  
2.4.4 OTHER PROBLEMS 
 
1) pH in the bulk of the solution might differ from the pH at the 
charged polyion surface which could influence the conformation and 
activity of proteins in addition to the interaction with the polyion layer 
itself. 
2) The relative roughness of the polyion surface. Polymeric tails might 
protrude into the bulk solution causing protein aggregation during 
adsorption. 
3) Drying of the polyion films might influence the structure.  
 
2.5 CONCLUSIONS 
 
 This chapter gives an overall view of fundamental approaches 
developed to design organized protein films with precise location of 
different protein monolayers. The multilayer film formation utilizing the 
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layer-by-layer methodology may be applied to any water-soluble protein 
by choosing a solution pH apart from the protein isoelectric point to 
provide a surface charge. The films can be used in the following 
application areas:   
 
1) Sensor layers. Multilayered films compromising enzymes layers 
provide a quick response to changes in its vicinity when combined 
with field-sensitive microelectronic elements. The efficiency of such 
sensor layers might be increased by the sequential deposition of the 
enzymatic layers that leads to enhanced electron transfer. Conductive 
polyions can be used to enhance electrical signaling processing as 
well. Protein/polyions multilayered films are insoluble in water and 
organic solvents and hence are perfectly suited for such uses.  
2) Biocompatible coatings. Multilayered protein films may be used to 
coat surfaces of implants and surgical instruments. The use of 
functional proteins allows the preparation of biomimetic surfaces. In 
addition, polymer and polyion organic chemistry is extensive and 
hundreds of polyions may be used in the assembly with proteins. 
Mmultilayered films that result are molecularly thin and have 
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desirable architecture and composition. The multilayered protein films 
may cover any type of surfaces that carries a sufficient surface charge.   
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CHAPTER III 
 
NITRIC OXIDE SYNTHASE OXYGENASE BASED NITRIC 
OXIDE RELEASE POLYETHYLENEIMINE THIN FILMS 
 
3.1 INTRODUCTION 
 
  Graft thrombosis is the cause of 80% of vascular access 
dysfunction, a problem with an associated health-care cost of over $1 
billion/year [1]. The number of revascularization procedures have 
increased dramatically, and is estimated at 15% after initial coronary 
revascularization, and approximately 50% after lower extremity bypass 
[2, 3]. Stent restenosis occurs at 30% of implant sites as a result of initial 
vascular thrombosis followed by cell proliferation, requiring a repeat 
angioplasty procedure within 1 year [4].  
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The thrombogenic nature of various polymeric materials utilized to 
prepare blood-contacting and implantable medical devices such as 
vascular grafts, intravascular catheters, sensors, coronary artery and 
vascular stents, and a host of other medical tools, even if labeled as 
biocompatible, can cause serious complications in patients. Thrombus 
formation at the surface of implantable medical devices is the major 
cause of vascular access dysfunction requiring secondary vascular 
procedures. Upon introduction of a foreign material into the blood 
stream, key proteins of the coagulation cascade (fibrinogen, and von 
Willebrand’s factor) adsorb on the surface, followed by platelet adhesion 
and activation, leading to fibrin and thrombus formation at the surface 
(Figure 3.1).  
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Protein adsorption 
and platelet 
recruitment 
Further thrombus 
growth 
Figure 3.1: Illustration showing thrombus formation at the surface 
of implantable medical devices. Upon exposure to blood, protein 
adsorption occurs, followed by platelet adhesion at the surface. 
Platelet activation leads to thrombus formation at the surface. 
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An anti-coagulation regiment, with the adverse effects associated 
with long term use, is typically required to clinically reduce the risk of 
thrombus formation [5]. Thrombus formation involves two synergistic 
events; a cGMP-dependant mechanism that involves platelet activation, 
adhesion and aggregation [6], and fibrin formation resulting from the 
binding of bivalent fibrinogen to glycoprotein IIb/IIIa [7]. 
Nitric oxide (NO), a molecule generated by the enzyme Nitric 
Oxide Synthase [8], using L-arginine as a substrate, was recently 
identified as a potent antiplatelet agent.  This small molecule orchestrates 
a myriad of vital physiological functions. For instance, the endothelium-
derived NO production at low concentrations (nanomolar) plays a critical 
role in the regulation of vascular hemostasis [9], and inhibits platelet 
adhesion [10], and aggregation [11], as well as their further recruitment 
to the growing thrombus [12]. There have been numerous reports 
indicating NO release from resting [13] and aggregating platelets [14]. 
NO flux from activated human platelets have been indirectly measured 
and is estimated at ~1.2 pmol.min-1/108 cells [13]. NO temporarily 
inactivates platelets in the close proximity of the endothelium [15]. This 
inhibition is short-lived and NO is rapidly scavenged by oxygen and 
hemoglobin in plasma [16]. To maintain this vital function and 
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counteract thrombus formation, stimulated human endothelial cells 
continuously generate NO at a level of ca. 4x10-10 mol.cm-2 min-1 [17]. In 
this regard, NO-releasing bio-polymers are targeted as effective anti-
thrombotic coatings in an attempt to enhance thromboresistivity of 
blood-contacting medical devices and implants. 
 Numerous approaches are investigated in an attempt to develop 
polymeric materials that are more blood-compatible. In general, these 
approaches can be categorized into two main trends: first, methods that 
mimic the anti-thrombogenic properties of endothelial cells [18], and, 
second, methods that use modified chemical surfaces and added moieties 
that limit protein and cell adhesion [19]. Prevention of protein adhesion 
in vivo is generally difficult to achieve, therefore the other approach, 
which aims at the development of surfaces mimicking properties of 
native endothelial cells, appears more promising. Nitric oxide, 
thrombomodulin, prostacyclin, and heparans contribute to the non-
thrombogenic properties of the endothelial cells [20]. A potential solution 
can be found in polymeric coating materials that are capable of releasing 
low levels of nitric oxide at the blood/coating interface. Considerable 
efforts in this research area are focused on improving the NO-release 
chemistry of materials used as outer coatings for implantable medical 
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devices. Polymers that possess chemical platforms with the ability of 
releasing NO have been shown to exhibit varying levels of 
thromboresistivity. In fact, akin to nitric oxide-releasing endothelial cells, 
NO-releasing polymers as functional coatings have the potential to be 
effective in preventing platelet adhesion, activation, and aggregation onto 
surfaces. These coatings have the potential of reducing the risk of 
thrombus formation at the exterior of blood-contacting devices and 
implants. They also have the potential to prolong vascular graft and stent 
potency without adverse systemic effects [21]. 
 Two classes of NO-releasing materials have been explored. N-
diazeniumdiolate based NO-releasing polymers [22], and Nitrosothiol-
based NO-releasing polymers [23]. N-diazeniumdiolates are inorganic 
NO donors formed by the reaction of a secondary amine structure with 2 
equivalents of NO gas under high pressure, creating a relatively stable 
adduct structure [24]. The general structural types of diazeniumdiolates 
used for NO-releasing polymers include dispersed non covalently bound 
small molecules where the diazeniumdiolate group is attached to amines 
in low molecular weight compounds, and covalently bound 
diazeniumdiolates group to polymeric side chains or to the polymeric 
backbone [22]. 
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 The second class of proposed NO donors are S-nitrosothiols [25]; they 
mimic biological systems that are thought to serve as a NO reservoirs and 
transporters, such as S-nitroso-albumin and S-nitrosoglutathione, which 
are the most abundant naturally occurring S-nitrosothiols circulating in 
blood [26]. 
 While films made of NO-donors incorporated into polymeric 
matrices did show the functional worthiness of NO-releasing coatings, 
this approach naturally results in only finite NO reservoirs, and thus the 
corresponding coatings are limited in their ability to sustain 
antithrombotic function over prolonged periods of time. The finite NO 
reservoir approach will also limit the potential use in more permanent 
types of implants. In addition, the NO fluxes achieved so far are lower 
than NO released from endothelial cells [19]. The logical alternative is 
then to explore approaches that would lead to materials with the ability to 
sustain NO generation for longer durations and at levels comparable to 
stimulated human endothelial cells (ca. 4x10-10 molcm-2min-1) [17] and/or 
potentially tunable levels.  
Developing NO-releasing surfaces that closely resembles the 
endothelium is critical to achieving better thromboresistivity. The 
endothelial isoform of the enzyme nitric oxide synthase, eNOS, is a key 
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component of the endothelial cell lining. It was reported that eNOS-
overexpressing endothelial cells seeding of synthetic small diameter 
vascular grafts decreased human platelet aggregation by 46%, and bovine 
aortic smooth muscle cell proliferation by 67.2% in vitro [27]. NO-
releasing materials using polyethyeleneimine (PEI), a biocompatible 
polymer [28], has been reported in literature [29]. In our lab, NO was 
successfully generated from the enzyme nitric oxide synthase embedded 
in bilayered cast surfactant films [30]. 
In this work, we incorporated the enzyme nitric oxide synthase in the PEI 
polymeric matrix by means of layer-by-layer electrostatic adsorption [8], 
to construct a multicomponent protein film that mimics the NO-
generating behavior of the endothelial cell lining. We demonstrate in this 
paper that our films provide a viable source of NO that utilizes 
endogenous compounds to maintain a continuous supply of nitric oxide. 
This study is the first account of successful NO release from the enzyme 
nitric oxide synthase incorporated into a bio-polymeric matrix using a 
LBL assembly technique. Our NO-releasing biopolymer coating is 
successfully formed by alternate deposition of polyethyleneimine and 
NO-generating NOS enzymes.  
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3.2 RESULTS AND DISCUSSION  
 
3.2.1 EXPRESSION AND PURIFICATION OF iNOSoxy VIA 
RECOMBINANT PLASMID DNA 
 
Many proteins and enzymes can be purchased through chemical 
catalogs with moderate expense making them best procured through 
those sources. NOS is not one of them. Because of the small biological 
quantities found in animal tissue, preparation and purification from 
biological sources would be prohibitively expensive. Making the 
procurement even more prohibitive is the fact that we need to specifically 
target the oxygenase domain of the enzyme, which could be obtained 
separate from the reductase domain by limited proteolysis of the full-
length strand. However, to use NOS enzyme in the quantities required for 
the completion of the current study requires an unbroken, relatively 
inexpensive source of enzyme without the tedious extra steps involved 
with enzyme proteolysis. This is accomplished through in-house protein 
expression and purification of the oxygenase domain via recombinant 
plasmid DNA. 
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The pCWori vector, a generous gift from the laboratory of Dennis 
Stuehr at the Lerner Research Institute, is inserted into plasmid DNA and 
transformed into BL21 (DE3) ampicillin-resistant E. coli as detailed by 
the Stuehr group [31]. This glycerol stock is then inoculated into 2 x 2 ml 
LB medium with 100 µg/ml added ampicillin and allowed to grow 
overnight at 37oC. 
Each aliquot of overnight culture is added to 500 ml autoclaved 
TB solution and allowed to grow under agitation at 37°C for about 3 
hours or until 0.1 OD600 is reached. Temperature is dropped to 25°C until 
0.3 – 0.8 OD600 is reached, at which time IPTG and δ-aminolevulinic acid 
are added to induce iNOSoxy protein production and to provide a heme 
precursor for the metalloprotein. The induced culture is left again 
overnight to produce maximum quantities of protein. Cells are harvested 
by centrifugation at 4,000 rpm at 4°C for 30 minutes, drained of 
supernate, and resuspended in a minimum of pH 7.6 lysis buffer 
containing base buffer, lysozyme, phenylmethanesulfonylfluoride 
(PMSF), Protease Inhibitor III (4-(2-Aminoethyl) benzenesulfonyl 
fluoride hydrochloride, aprotinin, leupetin, pepstatin A, bestatin, and L-3-
trans-Carboxyoxiran-2-carbonyl)-L-leucyl-agmatin), DNase, and MgCl2. 
Cells are lysed by sonication at 15-second on, 45-second off intervals for 
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a period of twenty minutes. The sonicated suspension is centrifugated at 
12,000 g at 4°C for 30 minutes to precipitate cellular debris. The debris 
pellet is discarded and the crude supernatant lysate is collected. Protein 
precipitation is induced by gradual addition of 0.300 g (NH4)2SO4/ml of 
solution over a period of 1 hour followed by centrifugation at 10,000 rpm 
to collect the protein pellet. The pellet is again resuspended in base 
buffer, PMSF, and Protease Inhibitor III and filtered through a 0.45 
micron PES syringe filter.  A 4 ml dead volume Ni-NTA Agarose 
column is prepared for use by charging with 50 mM NiSO4, followed by 
addition of a binding tris buffer before loading the filtered protein sample 
onto the column. The column is equilibrated with tris binding buffer and 
washed with a dilute (40 mM) imidazole wash buffer prior to elution 
with c. 200 mM imidazole elution buffer. The protein was collected off 
the column and dialyzed in 500 ml base buffer with 200 µl β-
mercaptoethanol, changing dialysis solution twice during the overnight 
process. The dialyzed protein is further concentrated by centrifugation at 
5000 rpm at 4°C using 30,000 MW cut-off Amicon filters until the 
desired concentration (usually 0.45 mM) is reached. Aliquots of the 
protein are stored at -80°C for future use. Protein concentration is 
determined by Bradford Assay and by UV-Vis analysis of the Soret band 
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at 421 nm. SDS-PAGE further confirms the presence of iNOSoxy by 
marker comparison to molecular weight standards. 
 
3.2.2 PREPARATION OF PEI/NOSoxy FILM 
 
We report here a proof of principle with the NOS oxygenase 
domain. The tetrahydrobiopterin-free oxygenase domain of inducible 
nitric oxide synthase (iNOSoxy) was expressed in house as reported in 
literature [32], and was used to explore the viability of nitric oxide 
synthase-containing films as potential sources of nitric oxide release.  
Although other surfaces can be used for film formation, we describe here 
the example of conductive pyrolytic graphite as a surface in order to 
perform, in parallel, the electrochemical characterization of nitric oxide 
synthase enzyme embedded in the polymetric film, as will be described 
later. The pyrolytic graphite surface is initially chemically oxidized as 
described in the literature to obtain a uniform negative charge at the 
surface [33]. The negatively-charge surface is then alternatively dip-
coated in polyethyleneimine (1.5 mg/ml) solution and iNOSoxy (20 
mg/ml) solution for 20 minutes, respectively, to achieve the desired film 
composition of 3 layers of iNOSoxy embedded in 4 alternate layers of 
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PEI unless stated otherwise. The surface is thoroughly washed with 
deionized water and air-dried after each dip-coating step. The films were 
stored overnight at 4°C. (Figure 3.2) 
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2.5% K2Cr2O7 
+1.5V-+1.7V 
PEI 1.5mg/ml NOSoxy  PEI 1.5mg/ml 
 
Figure 3.2:  Assembly of PEI/NOSoxy film using layer-by-
layer electrostatic deposition.  
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3.2.3 FT-IR SPECTROSCOPIC CHARACTERIZATION 
 
We first performed IR characterization of the iNOSoxy in PEI 
films. Figure 3.3 shows the IR spectrum of iNOSoxy sandwished in 
layers of PEI. The spectrum is focused in the amide-1 and amide-2 IR 
region, which is often used to probe structural changes in globular 
proteins. Figure 1 shows that the overall shapes and positions of the two 
amide-bands are conserved in PEI films compared to native iNOSoxy in 
the absence of PEI. This result shows that the iNOSoxy conserves its 
major globular structure features in the PEI thin film. 
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Figure 3.3:  Infrared spectrum in the amide I and amide II IR region 
showing that these bands, as spectroscopic probes of the NOSoxy 
structure in the PEI film, are conserved. 
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3.2.4 ELECTROCHEMICAL CHARACTERIZATION 
 
To characterize the functional integrity of iNOSoxy embedded in 
the PEI film, we examined the electrochemical reduction of NO by 
iNOSoxy in film at the surface of pyrolytic graphite electrodes. The 
experiments for the characterization of NOS functional integrity using 
NO are carried out in the absence of oxygen. For these experiments only, 
the buffer is typically purged with purified nitrogen for at least 30 min 
prior to the experiments. A nitrogen blanket was then kept over the 
solution throughout the experiments. A fresh solution of 2mM NO was 
prepared, and required aliquots are added to the solution to make the 
desired concentration increments. NO stock-solutions are made by 
bubbling pure NO gas through degassed water [34]. NOSoxy enzymes, 
like other heme proteins and P-450 enzymes, can catalyze the 
electrochemical reduction of the nitric oxide as a substrate [35, 36]. We 
used this known property to characterize the presence and function of 
iNOSoxy enzymes embedded between the PEI layers in our thin films. 
Cyclic voltammetry of PEI/iNOSoxy film at the surface of PG electrodes 
(Figure 3.4) illustrates an irreversible catalytic wave at –0.9V/s, a 
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response typical to the catalytic reduction of NO by a heme protein such 
as iNOSoxy [35, 36].  
A negative control experiment (PEI film devoid of iNOSoxy), 
does not show a catalytic current at –0.9V/s at the same NO 
concentrations (Figure 3.5). The increase in catalytic currents at –0.9V/s 
upon incremental additions of NO is a clear indication of iNOSoxy 
catalytic mediation, and further confirms that its structural integrity and 
catalytic function are preserved in the in our PEI films. The native 
structure and integrity of embedded NOS enzyme and related enzymatic 
function are critical to the successful fabrication of our targeted NOS-
based NO-releasing films.  
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Figure 3.4: Cyclic voltammograms of catalytic reductions of NO by 
PEI/NOS films at the surface of a PG electrode in pH 7.0 for different 
NO concentrations. The film on the electrode was formed by the alternate 
deposition of 5 layers of NOS enzyme sandwiched between PEI layers.  
 
 
 
 
 
 
 
Figure 3.5: Negative control showing no catalytic reduction of NO on 
PEI films devoid of iNOSoxy protein 
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3.2.5 ATOMIC FORCE MICROSCOPY 
 
 To investigate the success of our methodology in producing 
polymeric film coatings with the desired coverage and surface 
morphology, we further characterized our LBL deposition of film 
components using atomic force microscopy (AFM) imaging. Figure 3.6 
illustrates the AFM image of the layer-by-layer iNOSoxy/PEI film 
buildup. Figure 3.6A shows the 3D AFM image of the deposition of a 
layer of iNOSoxy over a layer of the polymer PEI at the surface of the 
HOPG slide. The figure shows a uniform distribution of the enzyme over 
the surface. Closer analysis of the features that result upon exposure to 
iNOSoxy solution confirms that the observed dimensions are close to the 
crystallographic dimension of iNOSoxy [37]. The overall surface height 
is of the order of 70 Å. Figure 3.6B shows the AFM image of the same 
HOPG slide after the sequential deposition of PEI over a layer of 
iNOSoxy resulting in the PEI/iNOSoxy/PEI coating. This image shows 
that the layer of iNOSoxy is still present but is now embedded in 
between two alternate PEI layers. The biocompatible polymeric coat now 
brings the average surface height to the order of 80 Å, which is consistent 
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with the cumulative surface heights measured for the PEI layers an the 
layer of iNOSoxy.  
Our step-by-step AFM characterization shows that the functional 
component of our films, i.e. the iNOSoxy enzyme, is successfully 
trapped in between layers of the PEI polymer. In addition, AFM imaging 
shows that our LBL methodology yields a thin film with uniform 
coverage of the surface. A uniform coverage of the surface is key for 
efficiently prohibiting seed contacts at the blood/device interface, which 
will help improve the thromboresistivity of the device. 
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Figure 3.6: Atomic force microscopy images at the surface of highly 
oriented pyrolytic graphite (HOPG) depicting typical PEI/NOS film 
composition. (A) is a 2µmx2µm 3D scan of a  layer of NOS enzyme 
deposited over a layer of PEI polymer. (B) is µmx2µm 3D scan of the 
final  layer of PEI polymer deposited after the deposition of a NOS 
enzyme layer.  
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3.2.6 QUARTZ CRYSTAL MICROBALANCE (QCM) 
CHARACTERIZATION 
 
Quartz Crystal Microbalance (QCM) was used as a tool to 
investigate mass changes upon the alternate deposition of PEI and the 
NOSoxy enzyme. QCM analysis was carried out at the surface of a thin 
oscillating quartz crystal sandwiched between two gold electrodes. The 
measurement of the resonant frequency changes at the surface of a 
modified quartz crystal with the alternate deposition of PEI and iNOSoxy 
at the surface of a quartz crystal indicates a decrease in frequency that 
correlates with mass increase at the surface. Figure 3.7A indicates a 
typical QCM plot of the frequency change ∆F0 upon the alternate 
deposition of PEI and the NOS enzyme on a quartz crystal. The average 
change in frequency per layer deposited is ∆F0= 120 Hz as indicated by 
Figure 3.7A.  
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Fig. 4.  
 
 
Figure 3.7:  A- Monitoring of the PEI/NOS multilayer film building 
through the layer-by-layer methodology using quartz crystal 
microbalance. B- Proposed model based on measured changes in crystal 
frequency showing that iNOSoxy in a monolayer of double-stack 
(vertical) dimers in each layer of iNOSoxy in the LBL process. 
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The change in frequency can be converted to mass changes by the 
Sauerbrey equation [38]. The mass change obtained in addition to the 
known dimensions of the iNOSoxy enzyme (60x50x40 Å), and the 
molecular weight of the iNOSoxy (60kDa) allows the determination of a 
model of the enzyme orientation within the PEI film. A monolayer of 
double-stacked iNOSoxy dimers (as seen in Figure 3.7B) corresponds to 
a theoretical ∆F0= 118 Hz which is of the same magnitude as the ∆F0 
seen experimentally. iNOSoxy is catalytically active in the dimeric form 
hence indicating that the charge-dependant orientation of the enzyme 
within the PEI matrix is such to retain its function. 
 
3.2.7 NITRIC OXIDE FLUX MEASUREMENTS 
 
Successful NO release was achieved from our PEI/NOS films and 
at fluxes higher than what have been reported in the literature for other 
inorganic NO-releasing systems [19]. Typical substrates prepared as 
described above are utilized to investigate the NO production capability 
from the trapped iNOSoxy enzymes. For the flux measurement of NO 
released from the NOS/PEI films, we used a reaction cocktail composed 
of the intermediate N-hydroxy-L-arginine (NHA; 100µM) [39], 
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tethrahydrobiopterin (H4B; 10µM), Dithiothreitol (DTT; 400µM) in 
phosphate buffer (100mM; pH=7.4). Hydrogen peroxide (H2O2) was 
used as a source of reducing equivalents in the known NOS peroxide 
shunt reaction. The enzymatic reaction was run at 37°C for the desired 
time period. The enzymatic activity of the PEI/NOS film was quantified 
by measuring NO released using the Griess assay [40] which tracks the 
accumulation of nitrite as the decomposition product of NO generated by 
iNOSoxy in the film. Figure 3.8 reveals total NO release from films 
composed of 3 consecutive layers of PEI/NOS. An increase in NO 
released is achieved with increasing time.  
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Figure 3.8: Total surface NO flux from PEI/NOS preparation as 
determined by the Griess assay. The PEI/NOS film is composed of 3 
layers of NOS enzyme sandwiched between alternate PEI polymer 
layers. n=6 
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Figure 3.9: NO surface flux vs time from PEI/NOS preparation as 
determined by the Griess assay. The PEI/NOS film is composed of 3 
layers of NOS enzyme sandwiched between alternate PEI polymer 
layers. n=6 
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Figure 3.9 shows the cumulative NO production by the 
(PEI/iNOSoxy) coating in terms of normalized NO surface flux. The 
figure shows that an initial burst of NO occurs at ~2 hours (6.377x10-10 
moles NO.min-1.cm-2 ± 0.523; n=6), 4 hours (3.611x10-10 moles NO.min-
1.cm-2 ± 0.177; n=6), 8 hours (1.913x10-10 moles NO.min-1.cm-2 ± 0.148; 
n=6), followed by a sustained release at 24 hours (0.707x10-10 moles 
NO.min-1.cm-2 ± 0.08; n=6), and 48 hours (0.511x10-10 moles NO.min-
1.cm-2 ± 0.088; n=6). Successful NO release was achieved from our 
PEI/NOS films and at fluxes higher than what have been reported in the 
literature for other inorganic NO-releasing systems.[19] Our 
PEI/iNOSoxy film sustained catalytic production of NO for long periods 
of time and in conditions that mimic physiologic settings. This proof of 
concept based on using NOS oxygenase domain shows that the enzyme, 
although trapped in the polymeric matrix, is still accessible by the N-
hydroxy-L-arginine as a substrate surrogate and hydrogen peroxide as a 
source of electrons in solution. Nitric oxide is produced as a result of the 
NOSoxy-mediated catalytic oxidation of N-hydroxy-L-arginine. Our 
enzyme-based NO production approach in the biocompatible PEI film 
closely mimics the behavior of endothelial cells and essentially 
overcomes the shortcoming of other approaches that result in only finite 
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NO-reservoirs. Sustained NO fluxes were observed for a period of 72 
hours. NO fluxes at 2 hours (6.377x10-10 molesNO.min-1.cm-2) are 150 
fold higher than fluxes from stimulated human endothelial cells (4x10-10 
mol.min-1.cm-2).[17] This initial burst eventually settles down at longer 
periods. For instance, the average NO flux at 48 hours is around only 
(0.511x10-10 molesNO.min-1.cm-2), a value that is still ten-fold higher 
than NO fluxes from stimulated human endothelial cells. In addition, 
they are over 1000-fold higher than NO released from platelets.[13] NO 
release from PEI films shows 2-phase kinetics: an initial burst of NO, 
followed by a sustained release over a longer period of time. This 2-
phase kinetics of NO release is in line with previously published 
studies.[41] The initial burst can be useful to counter early prosthetic 
graft occlusion that occurs in 18% of synthetic vascular access conduits 
for dialysis [42], and 25% of infrapoliteal synthetic grafts.[3] The 
PEI/NOS film has the ability to function as a thromboresistant scaffold 
that imitates the endothelial cell lining response through the biphasic NO 
release exhibited. 
To monitor the effects of film thickness on NO fluxes we 
investigated NO release from films with varying numbers of iNOSoxy 
layers. Figure 3.10 shows increased NO fluxes from a film composed of 
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5 layers of PEI/NOS relative to a film preparation of 3 layers of 
PEI/NOS, indicating that higher NO fluxes can be achieved by increasing 
the thickness, i.e. enzyme loading, of the polymeric coatings. The rate of 
NO release is crucial, and the optimum NO levels for coatings to be 
applied on medical devices and blood-contacting implants are yet to be 
determined. Therefore, the ability to control NO fluxes is of utmost 
importance. Our layer-by-layer approach provides the ability to control 
NO fluxes from films by varying the number of NOS enzyme layers in 
the polymeric matrix. In addition to producing nanometer-thick coatings, 
the layer-by-layer electrostatic self-assembly method has the built-in 
ability to tweak the film architecture to meet the requirements of 
thickness and composition.  
 
 
 
 
 
 
 
 
 90
2hrs (3layers) 2hrs(5layers) 4hrs(3layers) 4hrs(5layers) 
0
10
20
30
40
50
60
70
80
90
100
110
120
N
O
 p
ro
d
u
ct
io
n
 n
M
/m
in
cm
2
Time (hrs)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: NO fluxes from PEI/NOS films with various thicknesses as 
determined by the Griess assay. The PEI/NOS film is composed of 3 and 
5 layers of NOS enzyme sandwiched between alternate PEI polymer 
layers; time= 2hrs & 4hrs 
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Our results with 3 and 5 PEI/NOSoxy layers show that fluxes of NO 
release correlate with the number of enzyme layers present in the film. 
Increasing the number of iNOSoxy layers deposited within the PEI film 
yields higher NO fluxes, indicating the ability of our approach to fine-
tune NO fluxes to meet requirements of optimum release for varying 
applications. This work shows a proof of principle strategy to use NOS 
enzymes in biocompatible films to release NO. These functional films 
would thus counteract thrombosis on blood-contacting devices. A similar 
work using the full length NOS with its reductase and oxygenase 
domains will be presented in the next chapter and show that NO can be 
similarly produced using the substrate arginine and the native NADPH as 
a source of electrons. 
 
3.3 CONCLUSIONS 
 
We have presented a proof of principle of a new approach for 
making antithrombotic coatings for medical devices and implants based 
on NO release. Our alternative approach is based on using nitric oxide 
synthase enzyme as the functional unit in a polymeric film for catalytic 
production of NO. The approach can use endogenous compounds for 
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continuous NO release from biocompatible films under physiologic 
conditions.  We have demonstrated that NOS-based polymetric films 
successfully generate NO under physiologic condition at levels higher 
than those observed for endothelial cells. The level of NO release can be 
tuned through varying the number of NOS layers in the film buildup. We 
have shown that NO fluxes from our NOS-based PEI films are sustained 
for prolonged periods of time, which has the potential of producing 
efficient, long-term, antithrombotic coatings for medical devices and 
blood-contacting tools such as stents and catheters.  
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CHAPTER IV 
NO-RELEASE NITRIC OXIDE SYNTHASE-BASED 
BIOPOLYMERS 
 
 
4.1 INTRODUCTION 
 
Graft thrombosis is the cause of 80% of vascular access dysfunction, a 
problem with an associated health-care cost of over $1 billion/year [1]. 
The number of revascularization procedures have increased dramatically, 
and is estimated at 15% after initial coronary revascularization, and 
approximately 50% after lower extremity bypass [2,3]. Stent restenosis 
occurs at 30% of implant sites as a result of initial vascular thrombosis 
followed by cell proliferation, requiring a repeat angioplasty procedure 
within 1 year [4].  
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The thrombogenic nature of various polymeric materials utilized to 
prepare blood-contacting and implantable medical devices such as 
vascular grafts, intravascular catheters, sensors, coronary artery and 
vascular stents, and a host of other medical tools, even if labeled as 
biocompatible, can cause serious complications in patients. Thrombus 
formation at the surface of implantable medical devices is the major 
cause of vascular access dysfunction requiring secondary vascular 
procedures. Upon introduction of a foreign material into the blood 
stream, key proteins of the coagulation cascade (fibrinogen, and von 
Willebrand’s factor) adsorb on the surface, followed by platelet adhesion 
and activation, leading to fibrin and thrombus formation at the surface 
(Figure 4.1).  
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Protein adsorption 
and platelet 
recruitment 
Further thrombus 
growth 
Figure 4.1: Illustration showing thrombus formation at the surface 
of implantable medical devices. Upon exposure to blood, protein 
adsorption occurs, followed by platelet adhesion at the surface. 
Platelet activation leads to thrombus formation at the surface. 
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An anti-coagulation regiment, with the adverse effects associated 
with long term use, is typically required to clinically reduce the risk of 
thrombus formation [5]. Thrombus formation involves two synergistic 
events; a cGMP-dependant mechanism that involves platelet activation, 
adhesion and aggregation [6], and fibrin formation resulting from the 
binding of bivalent fibrinogen to glycoprotein IIb/IIIa [7]. 
Nitric oxide (NO), a molecule generated by the enzyme Nitric 
Oxide Synthase (NOS) using L-arginine as a substrate, was recently 
identified as a potent antiplatelet agent.  This small molecule orchestrates 
a myriad of vital physiological functions. For instance, the endothelium-
derived NO production at low concentrations (nanomolar) plays a critical 
role in the regulation of vascular hemostasis [8], and inhibits platelet 
adhesion [9], and aggregation [10], as well as their further recruitment to 
the growing thrombus [11]. There have been numerous reports indicating 
NO release from resting [12], and aggregating platelets [13]. NO flux 
from activated human platelets have been indirectly measured and is 
estimated at ~1.2 pmol.min-1/108 cells [12]. NO temporarily inactivates 
platelets in the close proximity of the endothelium [14]. This inhibition is 
short-lived and NO is rapidly scavenged by oxygen and hemoglobin in 
plasma [15]. To maintain this vital function and counteract thrombus 
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formation, stimulated human endothelial cells continuously generate NO 
at a level of ca. 4x10-10 mol.cm-2 min-1 [16]. In this regard, NO-releasing 
bio-polymers are targeted as effective anti-thrombotic coatings in an 
attempt to enhance thromboresistivity of blood-contacting medical 
devices and implants. 
 Numerous approaches are investigated in an attempt to develop 
polymeric materials that are more blood-compatible. In general, these 
approaches can be categorized into two main trends: first, methods that 
mimic the anti-thrombogenic properties of endothelial cells [17], and, 
second, methods that use modified chemical surfaces and added moieties 
that limit protein and cell adhesion [18]. Prevention of protein adhesion 
in vivo is generally difficult to achieve, therefore the other approach, 
which aims at the development of surfaces mimicking properties of 
native endothelial cells, appears more promising. Nitric oxide, 
thrombomodulin, prostacyclin, and heparans contribute to the non-
thrombogenic properties of the endothelial cells [19]. A potential solution 
can be found in polymeric coating materials that are capable of releasing 
low levels of nitric oxide at the blood/coating interface. Considerable 
efforts in this research area are focused on improving the NO-release 
chemistry of materials used as outer coatings for implantable medical 
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devices. Polymers that possess chemical platforms with the ability of 
releasing NO have been shown to exhibit varying levels of 
thromboresistivity. In fact, akin to nitric oxide-releasing endothelial cells, 
NO-releasing polymers as functional coatings have the potential to be 
effective in preventing platelet adhesion, activation, and aggregation onto 
surfaces. These coatings have the potential of reducing the risk of 
thrombus formation at the exterior of blood-contacting devices and 
implants. They also have the potential to prolong vascular graft and stent 
potency without adverse systemic effects [20]  
 Two classes of NO-releasing materials have been explored. N-
diazeniumdiolate based NO-releasing polymers [21], and Nitrosothiol-
based NO-releasing polymers [22]. N-diazeniumdiolates are inorganic 
NO donors formed by the reaction of a secondary amine structure with 2 
equivalents of NO gas under high pressure, creating a relatively stable 
adduct structure [23]. The general structural types of diazeniumdiolates 
used for NO-releasing polymers include dispersed non covalently bound 
small molecules where the diazeniumdiolate group is attached to amines 
in low molecular weight compounds, and covalently bound 
diazeniumdiolates group to polymeric side chains or to the polymeric 
backbone [21]. 
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 The second class of proposed NO donors are S-nitrosothiols [24]; they 
mimic biological systems that are thought to serve as a NO reservoirs and 
transporters, such as S-nitroso-albumin and S-nitrosoglutathione, which 
are the most abundant naturally occurring S-nitrosothiols circulating in 
blood [25]. 
 While films made of NO-donors incorporated into polymeric 
matrices did show the functional worthiness of NO-releasing coatings, 
this approach naturally results in only finite NO reservoirs, and thus the 
corresponding coatings are limited in their ability to sustain 
antithrombotic function over prolonged periods of time. The finite NO 
reservoir approach will also limit the potential use in more permanent 
types of implants. In addition, the NO fluxes achieved so far are lower 
than NO released from endothelial cells [18]. The logical alternative is 
then to explore approaches that would lead to materials with the ability to 
sustain NO generation for longer durations and at levels comparable to 
stimulated human endothelial cells (ca. 4x10-10 molcm-2min-1) [16], 
and/or potentially tunable levels.  
Developing NO-releasing surfaces that closely resembles the 
endothelium is critical to achieving better thromboresistivity. The 
endothelial isoform of the enzyme nitric oxide synthase, eNOS, is a key 
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component of the endothelial cell lining. It was reported that eNOS-
overexpressing endothelial cells seeding of synthetic small diameter 
vascular grafts decreased human platelet aggregation by 46%, and bovine 
aortic smooth muscle cell proliferation by 67.2% in vitro [26]. NO-
releasing materials using polyethyeleneimine (PEI), a biocompatible 
polymer [27], has been reported in literature [28]. In our lab, NO was 
successfully generated from the enzyme nitric oxide synthase embedded 
in bilayered cast surfactant films [29].  
NO releasing materials using Polyethyeleneimine (PEI), a biocompatible 
polymer [27], has been reported in literature [28,30,31]. In our lab, NO 
was successfully generated nitric oxide from the oxygenase domain of 
the enzyme Nitric Oxide Synthase (NOSoxy) embedded in polymeric 
matrix by means of layer-by-layer electrostatic adsorption [32,33]. In this 
work, we incorporated the enzyme nitric oxide synthase in the PEI 
polymeric matrix by means of layer-by-layer electrostatic adsorption 
[33], to construct a multicomponent protein film that mimics the NO-
generating behavior of the endothelial cell lining. We demonstrate in this 
paper that our films provide a viable source of NO that utilizes 
endogenous compounds to maintain a continuous supply of nitric oxide.  
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4.2 MATERIALS AND METHODS 
 
4.2.1 EXPRESSION AND PURIFICATION OF iNOS VIA 
RECOMBINANT PLASMID DNA 
 
Many proteins and enzymes can be purchased through chemical 
catalogs with moderate expense making them best procured through 
those sources. NOS is not one of them. Because of the small biological 
quantities found in animal tissue, preparation and purification from 
biological sources would be prohibitively expensive. Making the 
procurement even more prohibitive is the fact that we need to specifically 
target the oxygenase domain of the enzyme, which could be obtained 
separate from the reductase domain by limited proteolysis of the full-
length strand. However, to use NOS enzyme in the quantities required for 
the completion of the current study requires an unbroken, relatively 
inexpensive source of enzyme without the tedious extra steps involved 
with enzyme proteolysis. This is accomplished through in-house protein 
expression and purification of the full-length enzyme via recombinant 
plasmid DNA. 
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The pCWori vector, a generous gift from the laboratory of Dennis 
Stuehr at the Lerner Research Institute, is inserted into plasmid DNA and 
transformed into BL21 (DE3) ampicillin-resistant E. coli as detailed by 
the Stuehr group [34]. This glycerol stock is then inoculated into 2 x 2 ml 
LB medium with 100 µg/ml added ampicillin and chloramphenicol, and 
allowed to grow overnight at 37oC. 
Each aliquot of overnight culture is added to 500 ml autoclaved 
TB solution and allowed to grow under agitation at 37°C for about 3 
hours or until 0.1 OD600 is reached. Temperature is dropped to 25°C until 
0.3 – 0.8 OD600 is reached, at which time IPTG and δ-aminolevulinic acid 
are added to induce iNOS protein production and to provide a heme 
precursor for the metalloprotein. The induced culture is left again 
overnight to produce maximum quantities of protein. Cells are harvested 
by centrifugation at 4,000 rpm at 4°C for 30 minutes, drained of 
supernate, and resuspended in a minimum of pH 7.6 lysis buffer 
containing base buffer, lysozyme, phenylmethanesulfonylfluoride 
(PMSF), Protease Inhibitor III (4-(2-Aminoethyl) benzenesulfonyl 
fluoride hydrochloride, aprotinin, leupetin, pepstatin A, bestatin, and L-3-
trans-Carboxyoxiran-2-carbonyl)-L-leucyl-agmatin), DNase, and MgCl2. 
Cells are lysed by sonication at 15-second on, 45-second off intervals for 
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a period of twenty minutes. The sonicated suspension is centrifugated at 
12,000 g at 4°C for 30 minutes to precipitate cellular debris. The debris 
pellet is discarded and the crude supernatant lysate is collected. Protein 
precipitation is induced by gradual addition of 0.300 g (NH4)2SO4/ml 
over a period of 1 hour followed by centrifugation at 10,000 rpm to 
collect the protein pellet. The pellet is again resuspended in base buffer, 
PMSF, and Protease Inhibitor III and filtered through a 0.45 micron PES 
syringe filter.  A 4 ml dead volume Ni-NTA Agarose column is prepared 
for use by charging with 50 mM NiSO4, followed by addition of a 
binding tris buffer before loading the filtered protein sample onto the 
column. The column is equilibrated with tris binding buffer and washed 
with a dilute (40 mM) imidazole wash buffer prior to elution with c. 200 
mM imidazole elution buffer. The protein was collected off the column 
and dialyzed in 500 ml base buffer with 200 µl β-mercaptoethanol, 
changing dialysis solution twice during the overnight process. The 
dialyzed protein is further concentrated by centrifugation at 5000 rpm at 
4°C using 30,000 MW cut-off Amicon filters until the desired 
concentration (usually 0.45 mM) is reached. Aliquots of the protein are 
stored at -80°C for future use. Protein concentration is determined by 
Bradford assay and by UV-Vis analysis of the Soret band at 421 nm. 
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SDS-PAGE further confirms the presence of iNOS by marker 
comparison to molecular weight standards. 
 
4.2.2 PREPARATION OF PEI/NOS FILM 
 
The full length inducible nitric oxide synthase (iNOS) was 
expressed in house as reported in literature [35]. A pyrolytic graphite 
surface (unless indicated otherwise) was initially modified utilizing our 
diazonium method as described in the literature to obtain a uniform 
negative charge at the surface [36]. Typically, the PG surface is dipped in 
a mixture of 50mM p-aminobenzoate and 50mM sodium nitrite at 4˚C, in 
a 3 necked electrochemical cell. The potential is scanned between 0 and -
0.6 V vs Ag/AgCl leading to the covalent attachment of diazonium group 
on the surface, with a free carboxylic group (COO-). The pyrolytic 
graphite surface was alternatively dipped coated in a polyethyleneimine 
(PEI; 1.5mg/ml) solution and iNOS solution for 10 minutes respectively 
to achieve the desired film composition. The surface was thoroughly 
washed with deionized and air-dried after each step. The films were 
stored overnight at 4°C. (Figure 4.2) 
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2.5% K2Cr2O7 
+1.5V-+1.7V 
PEI 1.5mg/ml NOSoxy  PEI 1.5mg/ml 
 
Figure 4.2:  Assembly of PEI/NOS film using layer-by-layer 
electrostatic deposition.  
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4.2.3 QUARTZ CRYSTAL MICROBALANCE (QCM) 
CHARACTERIZATION 
 
QCM analysis was carried out at the surface of a thin oscillating 
quartz crystal sandwiched between two gold electrodes. Prior to coating, 
the quartz crystal surface surface was cleaned by soaking in a piranha 
solution (30%H2O2; 70%H2SO4) for 5 minutes, followed by rinsing with 
deionized water, and dried under nitrogen. The surface of the quartz 
crystal was modified, prior to deposition, with our diazonium method as 
previously described. We measured the reduction in resonance frequency 
with each deposited layer and calculated the mass deposited using the 
Sauerbrey equation, which directly relates the decrease in frequency to 
mass change [37]. QCM analysis was performed on a CH Instrument 
electrochemical workstation using a QCM cell; the same cell was used 
for electrochemical experiments needed to modify the gold surface prior 
to LBL depositions.  
 
 
 
 
 114
4.2.4 ATOMIC FORCE MICROSCOPY 
 
Atomic Force Microscopy characterization was carried out at the 
surface of 1cmx1cm highly oriented pyrolytic graphite (HOPG) slides. 
Initially, the top layer on the slide was peeled to eliminate any 
interference from dust particles. The HOPG surface was modified with 
the diazonium method as previously described. The surface was modified 
as previously described and images were taken following each layer 
deposition using a Molecular Imaging pico-SPM using the MAC mode 
interfaced with a PicoScan controller (MICorp, Arizona). 
 
4.2.5 NO FLUX MEASUREMENTS 
 
The films were prepared as described above. We prepared reaction 
cocktail composed of the substrate L-arginine at physiological levels 
(100µM) [38], 1mM Calcium Chloride (CaCl2) in Phosphate buffer 
(100mM; pH=7.4). NADPH (150µM) was used as a source of reducing 
equivalents, which is widely used in the NOS community. The enzymatic 
reaction was run at 37°C for the desired time period. The enzymatic 
activity of the film at the pyrolytic graphite surface was quantified by 
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measuring NO flux using the Griess assay [39,40]. Absorbance 
measurements were taken using an Agilent 8543 Spectrophotometer 
utilizing 1-cm path UV-visible cells. 
 
4.2.6 PLATELET ADHESION STUDIES 
 
Whole blood from dog was drawn into blood collection tubes 
containing 60 units of sodium heparin as an anticoagulant. The 
heparinized whole blood was centrifuged at 110g for 15 min at 228C. 
platelet-rich plasma (PRP) was collected from the supernatant. To re-
establish platelet activity, CaCl2 was added to the PRP to raise [Ca
2+] by 
2 mM. Before PRP incubation, the Indium Tin Oxide (ITO) slides were 
modified by the method described previously. Then, the polymer coated 
ITO slides were incubated for 1 h at 37˚C in 500 mL of recalcified PRP 
under static conditions. The PRP was then decanted and the wells were 
washed once with 200 mL PBS.  
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4.2.7 LACTATE DEHYDROGENASE ASSAY 
 
Before PRP incubation, the poly-L-Lysine coated microtiter plate 
wells were modified by the method described previously. Then, 100 mL 
of recalcified PRP was added to each polymer-coated well and incubated 
for 1 h at 37˚C under static conditions. The PRP was then decanted and 
the wells were washed once with 200 mL PBS. Adhered platelets were 
lysed using a lysing buffer which was 1% (w/v) Triton X-100. 150µL of 
lysing buffer was incubated in each well for 1 h at 37˚C with occasional 
agitation to completely disrupt the platelet membranes. Then, 100 µL of 
each lysate solution was pipetted into wells of a 96-well polystyrene 
microtiter plate (Fisher) that contained 100 µL of reagent from an LDH 
assay kit (Roche Applied Sciences, Indianapolis, IN), and incubated for 
30 min at 25˚C. Then, 50 µL of stop solution is added and absorbance of 
each well at 490 nm was monitored by a Labsystems Multiskan RC 
microplate reader.  
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4.3 RESULTS AND DISCUSSION 
 
4.3.1 QUARTZ CRYSTAL MICROBALANCE (QCM) 
CHARACTERIZATION 
 
Quartz Crystal Microbalance (QCM) was used as a tool to 
investigate mass changes upon the alternate deposition of PEI and the 
iNOS enzyme. QCM analysis was carried out at the surface of a thin 
oscillating quartz crystal sandwiched between two gold electrodes. The 
measurement of the resonant frequency changes at the surface of a 
modified quartz crystal with the alternate deposition of PEI and iNOS at 
the surface of a quartz crystal indicates a decrease in frequency that 
correlates with mass increase at the surface. Figure 4.4 indicates a typical 
QCM plot of the frequency change ∆F0 upon the alternate deposition of 
PEI and the NOS enzyme on a quartz crystal. The average change in 
frequency per layer deposited is ∆F0= 58 Hz as indicated by Figure 4.3.  
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Figure 4.3: A- Monitoring of the PEI/NOS multilayer film building 
through the layer-by-layer methodology using quartz crystal 
microbalance. B- Proposed model based on measured changes in crystal 
frequency showing that iNOSoxy in a monolayer of dimers in each layer 
of iNOSoxy in the LBL process. 
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The change in frequency can be converted to mass changes by the 
Sauerbrey equation [37]. The mass change obtained in addition to the 
known dimensions of the iNOS enzyme (120x80x60 Å), and the 
molecular weight of the iNOS (120kDa) allows the determination of a 
model of the enzyme orientation within the PEI film. A monolayer of 
iNOS dimers (as seen in Figure 4.3B) corresponds to a theoretical ∆F0= 
60 Hz which is of the same magnitude as the ∆F0 seen experimentally. 
iNOS is catalytically active in the dimeric form hence indicating that the 
charge-dependant orientation of the enzyme within the PEI matrix is such 
to retain its function. 
 
4.3.2 ATOMIC FORCE MICROSCOPY CHARACTERIZATION 
 
 To investigate the success of our methodology in producing 
polymeric film coatings with the desired coverage and surface 
morphology, we further characterized our LBL deposition of film 
components using atomic force microscopy (AFM) imaging. Figure 4.4 
illustrates the AFM image of the layer-by-layer iNOS/PEI film buildup. 
Figure 4.4A illustrates the 3D AFM image of the deposition of a layer of 
the polymer PEI at the surface of the HOPG slide. The figure shows a 
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uniform spread of the PEI polymer on the surface. The surface height is 
of the order of 2.0nm. Figure 4.4B shows the 3D AFM image of the 
deposition of a layer of iNOS over a layer of the polymer PEI at the 
surface of the HOPG slide. The figure shows a uniform distribution of 
the enzyme over the surface. Closer analysis of the features that result 
upon exposure to iNOS solution confirms that the observed dimensions 
are close to the crystallographic dimension of iNOS [42]. The overall 
surface height is of the order of 8.0nm. Figure 4.4C shows the AFM 
image of the same HOPG slide after the sequential deposition of PEI over 
a layer of iNOS resulting in the PEI/iNOS/PEI coating. This image shows 
that the layer of iNOS is still present but is now embedded in between 
two alternate PEI layers. The biocompatible polymeric coat now brings 
the average surface height to the order of 10.0nm, which is consistent 
with the cumulative surface heights measured for the PEI layers an the 
layer of iNOS.  
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FIGURE 4.4: Atomic force microscopy images at the surface of highly 
oriented pyrolytic graphite (HOPG) depicting typical PEI/NOS film 
composition. (A) is a 2µmx2µm 3D scan of the layer of PEI polymer 
deposited at the HOPG surface. (B) is a 2µmx2µm 3D scan of a  layer of 
NOS enzyme deposited over a layer of PEI polymer. (C) is a 2µmx2µm 
3D scan of the final  layer of PEI polymer deposited after the deposition 
of a NOS enzyme layer. 
 
A B 
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  Our step-by-step AFM characterization shows that the 
functional component of our films, i.e. the iNOS enzyme, is successfully 
trapped in between layers of the PEI polymer. In addition, AFM imaging 
shows that our LBL methodology yields a thin film with uniform 
coverage of the surface. A uniform coverage of the surface is 
instrumental in efficiently prohibiting seed contacts at the blood/device 
interface, which will help improve the thromboresistivity of the device. 
 
4.3.3 NO FLUX MEASUREMENTS 
 
Successful NO release was achieved from our PEI/NOS films and 
at fluxes higher than what have been reported in the literature for other 
inorganic NO-releasing systems [18]. Typical substrates prepared as 
described above are utilized to investigate the NO production capability 
from the trapped iNOS enzymes. The enzymatic activity of the coatings 
at the pyrolytic graphite surface was quantified by measuring NO flux 
using the Griess assay [39, 40], which tracks the accumulation of nitrite 
as the decomposition product of NO generated by iNOS in the film. 
Figure 4.5 reveals total NO release from films composed of 5 consecutive 
layers of PEI/NOS. An increase in NO released is achieved with 
increasing time.  
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Figure 4.5: Total surface NO flux from PEI/NOS preparation as 
determined by the Griess assay. The PEI/NOS film is composed of 5 
layers of NOS enzyme sandwiched between alternate PEI polymer 
layers. n=5 
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Figure 4.6 shows the cumulative NO production by the (PEI/iNOS) 
coating in terms of normalized NO surface flux. The figure shows that an 
initial burst of NO occurs at 24 hours (1.09nM NO.min-1.cm-2 ± 0.45; 
n=5), 48 hours (0.88nM NO.min-1.cm-2 ± 0.13; n=6), 72 hours (0.59nM 
NO.min-1.cm-2 ± 0.08; n=5), followed by a sustained release at 96 hours 
(0.54nM NO.min-1.cm-2 ± 0.12; n=5).  
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Figure 4.6: NO surface flux vs time from PEI/NOS preparation as 
determined by the Griess assay. The PEI/NOS film is composed of 3 
layers of NOS enzyme sandwiched between alternate PEI polymer 
layers. n=5 
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Successful NO release was achieved from our PEI/NOS films and 
at fluxes higher than what have been reported in the literature for other 
inorganic NO-releasing systems [18]. Our PEI/iNOS film sustained 
catalytic production of NO for long periods of time and in conditions that 
mimic physiologic settings. Our enzyme-based NO production approach 
in the biocompatible PEI film closely mimics the behavior of endothelial 
cells and essentially overcomes the shortcoming of other approaches that 
result in only finite NO-reservoirs. Sustained NO fluxes were observed 
for a period of 96 hours. This initial burst eventually settles down at 
longer periods. NO release from PEI films shows 2-phase kinetics: an 
initial burst of NO, followed by a sustained release over a longer period 
of time. This 2-phase kinetics of NO release is in line with previously 
published studies [43]. The initial burst can be useful to counter early 
prosthetic graft occlusion that occurs in 18% of synthetic vascular access 
conduits for dialysis [44], and 25% of infrapoliteal synthetic grafts [3]. 
The PEI/NOS film has the ability to function as a thromboresistant 
scaffold that imitates the endothelial cell lining response through the 
biphasic NO release exhibited. 
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To monitor the effects of film thickness on NO fluxes we 
investigated NO release from films with varying numbers of iNOS 
layers. Figure 4.7 shows increased NO fluxes from a film composed of 5 
layers of PEI/NOS relative to a film preparation of 3 layers, and 1 layer 
of PEI/NOS respectively, indicating that higher NO fluxes can be 
achieved by increasing the thickness, i.e. enzyme loading, of the 
polymeric coatings. The rate of NO release is crucial, and the optimum 
NO levels for coatings to be applied on medical devices and blood-
contacting implants are yet to be determined. Therefore, the ability to 
control NO fluxes is of utmost importance. Our layer-by-layer approach 
provides the ability to control NO fluxes from films by varying the 
number of NOS enzyme layers in the polymeric matrix. In addition to 
producing nanometer-thick coatings, the layer-by-layer electrostatic self-
assembly method has the built-in ability to tweak the film architecture to 
meet the requirements of thickness and composition.  
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Figure 4.7: NO fluxes from PEI/NOS films with various thicknesses as 
determined by the Griess assay. The PEI/NOS film is composed of 1,3 
and 5 layers of NOS enzyme sandwiched between alternate PEI polymer 
layers; time= 8hrs  
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Our results with 1, 3 and 5 PEI/NOS layers show that fluxes of NO 
release correlate with the number of enzyme layers present in the film. 
Increasing the number of iNOS layers deposited within the PEI film 
yields higher NO fluxes, indicating the ability of our approach to fine-
tune NO fluxes to meet requirements of optimum release for varying 
applications. 
 
4.3.4 PLATELET ADHESION STUDIES 
 
To evaluate the thromboresistivity of the NOS based polymeric 
coatings in vitro, ITO slides, glass substrates that offer the advantage of 
being conductive, were coated with the NOS containing polymer (Figure 
4.8B), as well as BSA containing polymer (Figure 4.8A) (negative 
control). Those slides were incubated with platelet rich plasma for 1 hour 
at 37°C, and then rinsed with PBS buffer. Phase contrast microscopy 
images of NO releasing NOS based polymers (Figure 4.8D) consistently 
showed almost no platelet adhesion at the surface when compared with a 
negative control (Figure 4.8C), indicating an overall enhancement of the 
thromboresistive properties of those coatings.  
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Figure 4.8: Phase contrast microscopy images pre-incubation of A) 
PEI/BSA film and B) PEI/NOS film, and post incubation with platelet 
rich plasma C) PEI/BSA film and D) PEI/NOS. 
 
 
A B 
C D 
 
 131
 
4.3.5 LACTATE DEHYDROGENASE ASSAY 
 
LDH assay is useful in quantifying cell and platelet adhesion at the 
surface of the PEI/NOS coatings. LDH is an enzyme found in cells at 
levels proportional to its size [45], and is released following cell 
breakdown. In vitro determination of the degree of platelet adhesion to 
surfaces using LDH assay has been reported [45-47].  
Figure 4.9 reveals the corresponding LDH level results of uncoated 
surface (bare) 0.16±0.04 (N=7), 5 layer coating (5 layers of NOS) 
0.11±0.01 (N=7), and 10 layer coating (10 layers of NOS) 0.06±0.01 
(N=7).  
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Figure 4.9: LDH assay of platelet adhesion on the surface of the 
PEI/NOS coatings. 
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In figure 4.10, the mean LDH activity at the bare surface was considered 
to correspond to 100% adhesion, and a decreased amount of adhered 
platelets was seen with the 5 layer coatings (69.8%) and with the 10 layer 
coatings (39.3%). 
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Figure 4.10: Percentage platelet adhesion on the surface of the PEI/NOS 
coatings. 
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As expected, the results presented reveals that the increasing 
number of NOS layers within the PEI/NOS coating corresponding to 
higher NO fluxes, reduced platelet adhesion in vitro up to 60.7%. The 
inhibition of platelet adhesion is a critical step in inhibiting thrombus 
formation at the surface of implantable medical devices.  The enhanced 
thromboresistivity displayed by these coatings provide the basis of future 
endeavors in developing more biocompatible coatings for surface 
modifications of implantable medical devices. 
 
4.4 CONCLUSIONS 
 
 Thrombus formation at the surface of implantable medical 
devices is the major cause of vascular access dysfunction requiring 
secondary vascular procedures. NO releasing bio-polymers are being 
sought as an effective anti-thrombotic coatings in an attempt to enhance 
thromboresistivity of those devices. The approaches utilizing NO-donors 
incorporated into polymeric matrices suffer from being a finite NO 
reservoir, and thus they are limited in their ability to sustain NO fluxes 
over a prolonged period of time. We presented a logical alternative that 
explores approaches aiming at developing materials with the ability to 
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sustain NO release for longer durations and at levels comparable to 
stimulated human endothelial cells (0.5-4x10-10 molcm-2min-1) [16].  
 NOS based polyethyleneimine coatings were successfully 
developed with the layer-by-layer methodology. NO was successfully 
generated from these coatings at levels comparable to stimulated human 
endothelial cells. NO release from these NOS-based coatings 
successfully decreased platelet adhesion at the surface by 60%, which 
potentially might lead to improved thromboresistivity of implantable 
devices when coated with those materials. 
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CHAPTER V 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
5.1 CONCLUSIONS   
 
During the past century, the use of implantable medical devices 
and other blood contacting biomedical devices have evolved from a mere 
dream to a widely adopted medical practice, including the use of stents, 
vascular grafts, sensors, pacemakers, heart valves, hemodialyzers, 
extracorporeal circuits, and membrane oxygenators [1, 2]. However, one 
of the major problems associated with these devices, is that the 
introduction of such devices leads to injury of the blood vessel walls. 
Clot formation or thrombosis also results at the injured site, causing 
stenosis or occlusion of the blood vessel. Moreover, if the medical device 
is left within the patient for an extended period of time, thrombus 
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ultimately forms on the device itself, again causing stenosis or occlusion. 
The driving force behind these issues is the lack of hemocompatibility of 
the polymeric materials used to prepare such devices. The 
biocompatibility of an implantable medical device is defined as the 
ability of the device to perform its intended function, with the desired 
incorporation within the host, without eliciting any undesirable local or 
systemic effects in that host [3]. There exists a need for modification of 
medical devices, with materials capable of enhancing the 
biocompatibility of these devices from the first instance of blood and 
tissue contact to days or weeks following its first use. The best-known 
example of a completely non-thrombogenic surface is the vascular 
endothelium that lines the inner walls of all blood vessels. The biological 
responses underlining the biocompatibility of this lining are mediated by 
a number of active molecules that are either expressed at the surface such 
as heparan sulfate, and thrombomodulin [4], or are continuously being 
secreted such as prostacyclin, plasminogen, antithrombin III and Nitric 
Oxide (NO) [5].  
  NO releasing bio-polymers are being sought as effective anti-
thrombotic coatings in an attempt to enhance thromboresistivity of those 
devices. The approaches utilizing NO-donors incorporated into polymeric 
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matrices suffer from being a finite NO reservoir, and thus they are 
limited in their ability to sustain NO fluxes over a prolonged period of 
time. The alternative is then to explore approaches that would lead to 
materials with the ability to sustain NO generation for longer durations 
and at levels comparable to stimulated human endothelial cells (0.5 - 
4x10-10 molcm-2min-1) [6]. NOS based polyethyleneimine coatings were 
successfully developed with the layer-by-layer methodology. NO was 
successfully generated from these coatings at levels comparable to 
stimulated human endothelial cells. NO release from these coatings 
successfully decreased platelet adhesion at the surface by 60%, which 
leads to improved thromboresistivity of implantable devices when coated 
with those materials. 
 
5.2 FUTURE DIRECTIONS 
 
 Various efforts have been made to prepare more blood 
compatible surfaces that include NO-release (anti-platelet activity), 
heparin bound (anticoagulant activity) [7], or thrombomodulin-
immobilized polymeric coatings [8]. The potency of such materials in 
preventing clot formation may be limited to the fact that these materials 
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partially address the thromboresistivity issues. These materials possess 
partial thromboreisistivity (either anti-platelet or anticoagulant activity). 
The alternative could be the development of surfaces that integrates both 
anti-platelet and anticoagulant agents that will act synergistically to 
achieve higher thromboresistivity levels. The integration of a 
combination of the agents that possess anti-platelet and anticoagulant 
activity into a polymeric matrix in such a manner that they are either 
released or are immobilized on the surface should result in a ‘truly’ 
biomimetic coating that closely resembles the endothelial cell lining of 
the inner blood vessel wall.  
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Figure 5.1: A schematic illustration of liposome surface glyco-
functionalization through the Staudinger ligation. Adapted from [9] 
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 Polymeric materials that combine NO release with surface-
bound heparin have been developed in an initial effort to towards the 
fabrication of polymeric coating that truly mimic the endothelial cell 
functionality [10]. Thrombomodulin, a 74 kDa transmembrane protein 
acts as a modulator of thrombin activity in vivo [4]. Once thrombin binds 
to thrombomodulin on the endothelial cell surface, thrombin’s fibrinogen 
cleaving activity is inhibited. In addition, the protein C anti-coagulation 
pathway is activated by this binding leading to the change of thrombin 
from a procoagulant state to an anti-coagulant state [11]. Multifunctional 
bilayer polymeric coatings have been recently described with both 
controlled NO release and surface bound active thrombomodulin or 
combined thrombomodulin and heparin that mimic the highly 
thromboresistant endothelium layers [12]. In addition, liposomes have 
been presented as candidates to prepare biomimetic coatings intended to 
enhance the biocompatibility of implantable medical devices [13]. 
Pancreatic Islets with recombinant azido-thrombomdulin were prepared 
by the chemoselective conjugation of an azido-functionalized 
thrombomodulin [14], to pancreatic islets by Staudinger ligation to a 
surface-bound bifunctional poly(ethylene glycol) linker (Figure 5.1). The 
presence of thrombomodulin on the surface was associated with a 
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significant increase in the production of activated protein C with a 
reduction in the islet-mediated thrombogenicity [9].  
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Figure 5.2: Schematic illustration of Liposomes that are capable of 
releasing Nitric Oxide with surface bound recombinant truncated 
thrombomodulin and heparin  
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Liposomes that are capable of releasing Nitric Oxide with surface bound 
thrombomodulin and heparin (Figure 5.2) appear to be a potential target 
to prepare biomimetic coatings that can be applied to surfaces of 
implantable medical devices to enhance their thromboresistivity and 
biocompatibility.  
We demonstrate in this chapter the preliminary work involving the 
sub-cloning of a methionine-deficient thrombomodulin construct, 
followed by the subsequent expression and purification of the 
recombinant truncated thrombomodulin containing an azido-
functionalized methionine analog as a C-terminal linker for site-specific 
functionalization using the Staudinger ligation [9]. 
 
5.2.1 Sub-cloning of Recombinant Truncated Thrombomodulin 
 
A DNA fragment encoding for the truncated human 
thrombomodulin, containing N-terminal BAMHI restriction site and a C-
terminal linker Gly Gly Met, was obtained by Polymerase Chain 
Reaction, by using the wild type thrombomodulin plasmid DNA as a 
template and primers Forward: 5'-
GGATCCGTACCCTAACTACGACCTGGTG-3', and Reverse: 5'-
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TTACATTCCACCTATGAGCAAGCCCGAATG-3'. The TOPO TA 
vector kit was used for the sub-cloning of the PCR products and the 
subsequent analysis of positive clones by restriction digestion using the 
BAMH I restriction enzyme. Site-directed mutagenesis was performed 
using primers Forward: 5’-CAGGTGCCAGCTGTTTTGCAACC-3’ and 
Reverse: 5’-GGTTGCAAAACAGCTGGCACCTG-3’ to generate a 
leucine (Leu) substitution for methionine-407 (M407L). The final 
construct (recombinant truncated thrombomodulin) was then inserted 
using the BAMHI site of the expression plasmid pET-39b(+) (Figure 
5.3). The expression plasmid pET-39b(+) containing the recombinant 
thrombomodulin insert was sequence-verified and subsequently 
transformed into the E.coli methionine auxotroph B834(DE3).  
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Figure 5.3: DNA gel electrophoresis depicting the size of the insert 
ligated with the pET-39b (+) plasmid. 
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5.2.2 Protein Expression and Purification 
 
M9 minimal medium (500 mL), supplemented with 1 mM MgSO4, 
0.4 wt % glucose, 1mg/L thiamine chloride, 0.1 mM CaCl2, kanamycin 
(30mg/L), and all proteinogenic amino acids (40 mg/L), was inoculated 
with 20 mL of an overnight culture of the transformed cells. When the 
turbidity of the culture reached an OD600 of 0.8, protein expression was 
induced by addition of isopropyl-â-D-thiogalactopyranoside (IPTG) to a 
final concentration of 0.5 mM. After 5 min, the medium was exchanged 
to remove methionine, cells were sedimented (4000g for 20 min), and the 
cell pellet was washed twice with 200 mL of 1X M9 salts. Cells were 
resuspended in 500 mL of the M9 minimal medium described above, 
without methionine but supplemented with 100 mg/L of azido-
functionalized methionine analogue. Cultures were grown for 4.5 h at 37 
°C. The cells were first harvested by centrifugation at 4 °C at 10000g for 
30 min and resuspended in 25mL of M9 buffer (1X M9 salts, 10% 
glycerol, 1 mg/mL lysozyme, and 10 µg/mL PMSF), and then the cells 
were lysed by sonication. The cell lysate was clarified by centrifugation 
at 10000g for 20 min. The supernatant was filtered through a 0.45µm 
syringe filters and then loaded onto a His-tag column. The presence of 
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thrombomodulin as an end product was confirmed using SDS-PAGE and 
quantified using S TAG rapid assay. Lane 5, features a band that 
corresponds to 36kDa in size confirming the presence of the truncated 
recombinant thrombomodulin. The average yield is 9.24mg of protein per 
liter of cell culture. 
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Figure 5.4: SDS PAGE of purified methionine deficient truncated 
recombinant thrombomodulin 
 
 
 
 
 
 
 
36 kDa 
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